GlassScriptPhysician profile
Ami S Patel
NPI 1407895907
$2,983.54
in general payments reported to CMS, 2019-2025
31 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $51.74 · 2022: $76.36 · 2023: $302 · 2024: $1,166 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $482.11 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $319.07 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $280.03 | 2019-2025 | |
| Intra-Sana Laboratories | $167.14 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Pfizer INC. | $157.26 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.86 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $87.89 | 2025 | Voquezna |
| Astellas Pharma US INC | $76.84 | 2024-2025 | Veozah |
| Bausch Health US, LLC | $69.38 | 2024-2025 | Aplenzin, Wellbutrin |
| Ironwood Pharmaceuticals, INC | $63.45 | 2019-2024 | Linzess |
| Idorsia Pharmaceuticals US INC | $61.39 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $58.88 | 2023-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.04 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $37.16 | 2024-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $34.53 | 2025 | Contrave |
| Acella Pharmaceuticals, LLC | $34.43 | 2024 | NP Thyroid 60 |
| Actelion Pharmaceuticals US, INC. | $28.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.63 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $26.72 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $22.04 | 2023 | Invega Sustenna |
| Abbott Laboratories | $21.98 | 2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $17.37 | 2019 | |
| Merck Sharp & Dohme LLC | $15.61 | 2019 | |
| Amgen INC. | $15.15 | 2025 | Repatha, Otezla |
| Scynexis, INC. | $15.13 | 2022 | |
| Exeltis, USA INC. | $14.27 | 2024 | Slynd |
| Adlon Therapeutics L.P. | $13.94 | 2019 | |
| Assertio Therapeutics, INC. | $13.25 | 2019 | |
| Almatica Pharma LLC | $12.81 | 2022 | |
| Ibsa Pharma INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.